Location Directory

Clinical trials in Dallas, Texas

This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13791

Shown on this page

Current sort

Institutions in Dallas

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UT Southwestern Medical Center

Live official records

Open in full search

Conditions: Microvascular Inflammation
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Orange, California + 19 more

Conditions: Heart Failure, Diabetes
Interventions: Message with EchoGo, Standard Message; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
Interventions: AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab; Procedure · Drug
Lead sponsor: Vijendra Singh; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Neurotrophic Keratopathy
Interventions: RGN-259, Placebo; Drug
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 41
States / cities: Vestavia Hills, Alabama • Laguna Hills, California • Loma Linda, California + 36 more

Conditions: Cervical Cancer
Interventions: TIVDAK; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 134
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 73 more

Conditions: Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions: AP01, Placebo; Drug · Other
Lead sponsor: Avalyn Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 61
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more

Conditions: Diabetic Kidney Disease
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 2,376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more

Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions: Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 69
States / cities: Anchorage, Alaska • Goodyear, Arizona • Clovis, California + 66 more

Conditions: Asthma
Interventions: tilrekimig, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: River Forest, Illinois • Hannibal, Missouri • The Bronx, New York + 8 more

Conditions: Heart Failure, Acute Decompensated Heart Failure
Interventions: Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Clostridoides Difficile Associated Disease
Interventions: C.difficile vaccine, Saline Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 32,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 142
States / cities: Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more

Conditions: HIV Infections
Interventions: VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more

Clinical trials in Dallas, Texas

Filter and sort this location

Institutions in Dallas

Live official records

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Pentoxifylline in Diabetic Kidney Disease

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)